Table 2. Most common treatment regimens across entire time period.

Regimen	n (%)
Most common first-line regimens (n=2,912)
Fluoropyrimidine†, oxaliplatin	725 (24.9)
Platinum‡, taxane¶	511 (17.5)
Single-agent fluoropyrimidine†	280 (9.6)
Fluoropyrimidine†, platinum‡, taxane¶	192 (6.6)
Anthracycline§, fluoropyrimidine†, oxaliplatin	177 (6.1)
Doxorubicin or epirubicin, fluoropyrimidine†, platinum‡	117 (4.0)
Fluoropyrimidine†, oxaliplatin, trastuzumab	109 (3.7)
Fluoropyrimidine†, platinum‡	90 (3.1)
Fluoropyrimidine†, oxaliplatin, taxane¶	70 (2.4)
Most common second-line regimens (n=1,230)
Ramucirumab, taxane¶	203 (16.5)
Fluoropyrimidine†, oxaliplatin	155 (12.6)
Platinum‡, taxane¶	101 (8.2)
Fluoropyrimidine†	73 (5.9)
Fluoropyrimidine†, irinotecan	73 (5.9)
Taxane¶	66 (5.4)
Ramucirumab	53 (4.3)
Anthracycline§, fluoropyrimidine†, oxaliplatin	31 (2.5)
Fluoropyrimidine†, oxaliplatin, trastuzumab	31 (2.5)
Fluoropyrimidine†, platinum‡, taxane¶	30 (2.4)

^†, fluoropyrimidine = 5-FU or capecitabine; ^‡, platinum = cisplatin or carboplatin; ^§, anthracycline = doxorubicin or epirubicin; ^¶, taxane = paclitaxel or docetaxel.